The second day of the AACR Virtual Annual Meeting II began with a clinical trials plenary session. Two of the session’s presentations, which focused on immunotherapy clinical...
Immunotherapy research has exploded over the past decade and has led to the approval of seven immune checkpoint inhibitors by the United States Food and Drug Administration (FDA) for the treatment...
Clinical trials were a major focus of the AACR Virtual Annual Meeting I, spanning nine plenary sessions over the two-day...
Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting...
A short time after Mallika Lala, PhD, finished her presentation titled “Pembrolizumab 400 mg Q6W dosing: First clinical outcomes...
The cutting-edge scientific program for the AACR Virtual Annual Meeting I began Monday, April 27, with an Opening Clinical Plenary featuring...
“These are extraordinary times,” began Hugh Auchincloss, MD, as he opened up the recent NIH-AACR Cancer, Autoimmunity, and Immunology...
By Meghali Goswami Meghali Goswami is a PhD candidate in the George Washington University – National Institutes of Health Graduate Partnerships Program and is currently...
The advent of immunotherapy has led to durable responses for an increasing number of patients, including many who initially...
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words...